Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-19 01:42 CEST (UTC+2h)

What's the problem? [Regulatives / Guidelines]

posted by nobody - 2017-05-17 09:31  - Posting: # 17364
Views: 6,950

PS: No, I don't think that assay performance will do anything to intraindiv. CV of a drug product, as long as

- not practically all samples are around LLOQ
- effects are not random.

Did some sims in the old daysTM, effect of assay when validated according to current recommendations is negligible.

Especially for the "11% CV in 5 other trials, suddenly 40% in my trial" example there is no explanation remotely related to assay.

Kindest regards, nobody

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,385 posts in 3,905 threads, 1,172 registered users;
online 12 (1 registered, 11 guests [including 10 identified bots]).

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed